Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 18:11:1221-9.
doi: 10.2147/NDT.S60518. eCollection 2015.

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Rachel Babij  1 , Jai S Perumal  1
Affiliations
Review

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Rachel Babij et al. Neuropsychiatr Dis Treat. .

Abstract

Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a prolonged T-cell lymphopenia results with emergence of a reconstituted immune system that differs in its composition from that pretreatment. In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. Despite this, the occurrence of serious secondary autoimmune disorders, infections, and a potential risk of malignancy necessitates a careful evaluation of risks versus benefits for an individual patient prior to its use. The requirement of patient commitment to the intense mandatory monitoring program is also a factor to be considered when incorporating alemtuzumab into the treatment regimen.

Keywords: alemtuzumab; comparative efficacy; multiple sclerosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Vukusic S, Confavreaux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20(3):369–374. - PubMed
    1. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112:133–146. - PubMed
    1. Jeffrey S. FDA approval for alemtuzumab (Lemtrada) in MS. Medscape Medical News. 2014. [Accessed April 9, 2015]. Available from: http://www.medscape.com/viewarticle/834994.
    1. Sorensen P. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014;27(3):246–259. - PubMed
    1. Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care. 2013;19(17 Suppl):343–354. - PubMed

LinkOut - more resources